BridgeMD
Compares treatment options for Rib Fractures
Official title Low Dose Dexmedetomidine Versus Normal Saline in Multiple Fracture Ribs
ClinicalTrials.gov ID: NCT04928300
What this study is testing
What is Dexmedetomidine?
Dexmedetomidine is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for rib fractures.
Also referred to as Precedex.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- In our study, we assess the diaphragmatic function, pain quality and anti-inflammatory properties between low dose infusion of dexmedetomidine normal saline in patients with multiple fracture ribs on conservative treatment.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Adults (age 18-65 years) of American Society of Anaesthesiologists (ASA) physical status I-II
- Traumatic multiple fracture ribs 3 ribs or more, who will be subjected to thorough assessments including chest 3D-CT
- Undergoing conservative treatment (chest strappings)
- Intractable pain with visual analogue scale (VAS) over 6 after traditional therapies
- Glasgow Coma Scale (GCS) ≥ 13.
You likely can't join if
- Multiple traumas to body parts other than chest with an abbreviated injury scale over 3
- Serious head trauma with a Glasgow coma scale lower than 13
- Mechanically ventilated patients
- Massive hemothorax
- Injury to the trachea or bronchus with requirement for immediate surgery
- Dementia
See the full eligibility criteria
- Adults (age 18-65 years) of American Society of Anaesthesiologists (ASA) physical status I-II
- Traumatic multiple fracture ribs 3 ribs or more, who will be subjected to thorough assessments including chest 3D-CT
- Undergoing conservative treatment (chest strappings)
- Intractable pain with visual analogue scale (VAS) over 6 after traditional therapies
- Glasgow Coma Scale (GCS) ≥ 13.
- Multiple traumas to body parts other than chest with an abbreviated injury scale over 3
- Serious head trauma with a Glasgow coma scale lower than 13
- Mechanically ventilated patients
- Massive hemothorax
- Injury to the trachea or bronchus with requirement for immediate surgery
- Dementia
- Use of corticosteroids during ICU stay
- Sepsis
- Continued use of neuromuscular blocking agents and aminoglycosides antibiotic use as they are known risk factors for ICU-acquired weakness and any known hypersensitivity
- Contraindication to the study drugs.
The study team makes the final eligibility decision.
Where it's taking place
- Asyut, Assuit, Egypt
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Asyut, Assuit, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.